EARL O. G. SCHMITT, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Myasthenia gravis, or Erb-Goldflam disease, may be defined as a disease characterized by an incapacity on the part of the voluntary motor system for sustained effort.1 It is a disease of the muscles themselves without involvement of the nervous system and affects most commonly the muscles of the eyes, those of the face, and the muscles of mastication.
The disease was first described by Wilkes in 1877. Erb, in 1878, characterized the condition as being a combination of bulbar symptoms, ptosis, and weakness of the muscles of mastication and of the muscles of the back of the neck.
SCHMITT EOG. THE USE OF GLYCINE IN THE TREATMENT OF MYASTHENIA GRAVIS*. Ann Intern Med. 1934;7:948–959. doi: https://doi.org/10.7326/0003-4819-7-8-948
Download citation file:
Published: Ann Intern Med. 1934;7(8):948-959.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use